Coherus BioSciences stock (US19247A1007): earnings miss keeps focus on turnaround plans

Coherus BioSciences reported a wider first?quarter loss and lower?than?expected revenue, keeping investor attention on its biosimilar and immuno?oncology strategy as the stock trades at penny?stock levels on Nasdaq.

Coherus BioSciences reported a first?quarter 2024 net loss and revenue below analyst expectations, underscoring the pressure on the biotech’s turnaround efforts as it shifts from a single?product focus on biosimilar Humira to a broader portfolio in oncology, according to Zacks Investment Research as of 05/09/2024.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: CHRS
• Sector/industry: Biotechnology, pharmaceuticals
• Headquarters/country: United States
• Core markets: Biosimilars and oncology therapies in the US and selected international markets
• Key revenue drivers: Biosimilars to blockbuster biologic drugs and immuno?oncology products
• Home exchange/listing venue: Nasdaq (ticker: CHRS)
• Trading currency: US dollar (USD)

Coherus BioSciences: core business model

Coherus BioSciences is a US?based biotechnology company focused on developing and commercializing biosimilar medicines and immune?oncology therapies. The business initially built its profile with biosimilars that reference blockbuster biologics, targeting high?cost treatments in areas such as immunology and oncology. This strategy aims to offer lower?priced alternatives while capturing meaningful market share.

The company’s early growth was closely tied to its biosimilar to adalimumab, the active ingredient in Humira, one of the world’s best?selling drugs before loss of exclusivity. Coherus pursued partnerships and commercialization agreements to distribute its versions in the US market, positioning itself among several competitors in the post?patent environment. As more players entered, pricing pressure and rebate dynamics intensified, making scale and portfolio breadth increasingly important.

To reduce reliance on a single franchise, Coherus has been shifting towards a diversified portfolio that includes oncology and immunology assets. This includes both additional biosimilars and novel immuno?oncology candidates designed to enhance anti?tumor immune responses. Management has highlighted this transition in earnings communications, emphasizing the long?term potential of a broader product mix alongside continued cost control.

The company’s economic model combines internally developed assets with in?licensed or partnered programs. Up?front payments, milestone structures, and profit?sharing agreements are typical features in such deals, affecting reported revenue and expenses over time. For investors, the mix of royalty?like inflows, product sales, and R&D spending creates a financial profile that can be volatile from quarter to quarter, especially while several programs are still in development.

Recent earnings: Q1 2024 loss and revenue miss

In its first?quarter 2024 report, Coherus posted a net loss and revenue that came in below consensus estimates, according to Zacks Investment Research as of 05/09/2024. Zacks noted that both sales and earnings per share were weaker than expected, reflecting ongoing competitive pressure in biosimilars and the cost of advancing the company’s oncology pipeline.

The quarter covered by that update was the three months ended March 31, 2024, and represented one of the early periods in which Coherus was operating with a more diversified portfolio rather than a single dominant biosimilar. While detailed line items were not highlighted in the summary, the report pointed to lower?than?forecast product revenue and an adjusted loss per share that exceeded the consensus loss. Such negative surprises can be significant for smaller biotech names that rely on capital markets access.

Management communications around that time emphasized cost discipline and portfolio reprioritization. The company has previously implemented restructuring measures to align its expense base with expected revenue, including reductions in operating costs and a focus on higher?priority clinical programs. However, the Q1 2024 performance showed that the path to sustained profitability remains challenging amid aggressive competition and evolving reimbursement trends in the US.

For market participants, an earnings miss can increase attention on liquidity, cash burn, and upcoming catalysts. In Coherus’ case, the balance between commercial biosimilar revenue and investment in pipeline assets is a central theme. If commercial products fail to ramp as anticipated, the company may need to reassess timelines or funding options for certain programs, which in turn can influence sentiment toward the stock.

Main revenue and product drivers for Coherus BioSciences

Coherus has focused much of its commercial strategy on biosimilars that reference high?value biologic drugs, especially in immunology and oncology indications. Biosimilars are designed to be highly similar to an already approved biologic, with no clinically meaningful differences in safety or effectiveness. They typically enter the market at a discount, generating savings for payers while providing manufacturers with meaningful volumes if they can secure formulary access.

Within this framework, the company’s biosimilar to Humira has been a key revenue driver. In the US market, 2023 and 2024 saw a wave of adalimumab biosimilar launches, leading to intense pricing competition and complex contracting. Coherus, like other participants, has had to balance list price, discounts, and net realized price to win share. The ability to secure positions with major pharmacy benefit managers and integrated health systems plays a central role in the revenue contribution of this product line.

Beyond adalimumab, Coherus is working on or commercializing other biosimilars, some of which target oncology indications. Oncology biosimilars can address supportive?care therapies and anti?cancer biologics, potentially diversifying the company’s revenue base. These products often require specialized distribution and strong relationships with hospital systems and oncology practices, which can take time to build but may lead to more durable revenue streams once established.

The company is also investing in immuno?oncology assets, aiming to develop novel agents that modulate the immune system to better recognize and attack tumors. Such programs can include checkpoint modulators or other mechanisms designed to enhance existing therapies. While these candidates are typically earlier?stage and carry higher development risk, they also offer the prospect of less crowded markets and potentially higher margins if successfully commercialized.

In addition, licensing and collaboration agreements contribute to Coherus’ revenue framework. Under such arrangements, the company may receive upfront payments, milestones tied to development or commercial progress, and royalties on net sales. The timing of these payments can cause periodic spikes in revenue, making it important for investors to differentiate between recurring product sales and one?time or infrequent collaboration inflows when assessing the underlying trajectory.

Stock performance and market perception

Coherus trades on Nasdaq under the ticker CHRS, placing it within a widely followed universe of US biotechnology names. In recent trading, the stock has been at low single?digit levels, reflecting both company?specific challenges and broader caution toward smaller, loss?making biotech firms. Penny?stock territory can amplify share price swings as news and sentiment shifts have a greater relative impact on market capitalization.

Biotech names with ongoing losses often experience elevated volatility when earnings or clinical updates are released. For Coherus, the Q1 2024 revenue miss and loss highlighted by Zacks reinforced concerns about the pace at which commercial products can offset R&D and operating expenses. At the same time, the stock’s depressed level can draw interest from investors who specialize in turnaround or deep?value scenarios, particularly those focused on healthcare and pharmaceuticals.

External commentary has also placed Coherus within a broader group of healthcare stocks where analysts remain cautious but alert to potential upside. An overview discussing sentiment around Immunome and Coherus mentioned that analysts are focused on future clinical and commercial execution rather than near?term earnings contributions, according to MarketBeat as of 05/16/2026. This underscores that expectations hinge on the company’s ability to deliver on its pipeline and commercial strategies.

Liquidity and daily trading volumes are important considerations for US investors, especially those managing larger portfolios. Coherus’ Nasdaq listing provides access to electronic trading infrastructure and a broad pool of counterparties, but tighter free float and concentrated ownership can still result in wider bid?ask spreads. For market participants, monitoring average daily volume and order book depth can be crucial when considering position sizing in a relatively small?cap biotech name.

Industry trends and competitive position

The biosimilar industry has matured significantly in recent years, with multiple manufacturers competing around the same reference biologics. In the US, regulatory guidance and payer practices have evolved to encourage biosimilar adoption, but real?world penetration has varied by product and therapeutic area. Large incumbents and generic drug makers bring scale advantages, which can pressure margins for smaller players like Coherus.

One of the defining features of the current biosimilar landscape is the intense focus on price competition combined with a need for robust manufacturing and pharmacovigilance capabilities. Companies must invest in high?quality production and supply chain reliability while accepting lower prices relative to originator products. For Coherus, maintaining cost?competitive manufacturing and efficient commercialization operations is central to sustaining its position in crowded markets.

In oncology and immuno?oncology, the competitive environment is shaped by both large pharmaceutical companies and emerging biotechs. Novel mechanisms, combination strategies, and biomarker?driven approaches are areas of active research. Coherus operates here as a smaller challenger, aiming to carve out space with differentiated assets or by targeting niches that are less saturated. Collaborations with larger partners can be a way to access development expertise and commercial infrastructure where needed.

Regulatory frameworks in the US and other major markets are generally supportive of biosimilar development, offering pathways that leverage existing clinical data from reference products. However, requirements for analytical similarity, immunogenicity assessment, and post?marketing surveillance remain stringent. The ability to navigate this environment and achieve timely approvals is a key competitive factor. Coherus’ track record with prior approvals suggests operational experience, but each new product presents its own regulatory and commercial challenges.

Why Coherus BioSciences matters for US investors

For US investors, Coherus offers exposure to two important healthcare themes: the expansion of biosimilars and the pursuit of innovative oncology therapies. Biosimilars are seen as a tool for controlling healthcare costs in Medicare, Medicaid, and commercial insurance plans, which makes the segment strategically relevant for the US system. Companies able to deliver reliable, lower?cost alternatives can benefit from structural tailwinds as payers look to manage drug spending.

At the same time, immuno?oncology remains a major focus of biomedical innovation in the US, driving substantial R&D investment across the industry. Coherus’ participation in this space, although smaller scale compared with large pharmaceutical groups, positions it within a field where breakthroughs can materially change a company’s trajectory. From a portfolio perspective, exposure to such a name can complement holdings in larger, more diversified healthcare companies.

Investors based in the US may also see Coherus as a case study in how smaller biotechnology firms navigate the transition from a single?product focus to a multi?asset portfolio. The company’s strategic decisions on capital allocation, licensing, and commercialization can provide insights into broader sector dynamics. Its Nasdaq listing and reporting in US dollars further simplify integration into domestic equity strategies and sector?focused funds.

Conclusion

Coherus BioSciences stands at a turning point as it works to broaden its portfolio and move beyond dependence on a single major biosimilar. The first?quarter 2024 revenue miss and ongoing losses highlight the execution risk that comes with this strategy, particularly in highly competitive markets. At the same time, the combination of biosimilars and immuno?oncology assets places the company in segments that are central to the future of US healthcare spending and cancer treatment. For market participants, the key questions revolve around how effectively Coherus can scale its commercial operations, manage costs, and advance its pipeline over the next several years.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.